Sunvic Bio

Sunvic Bio is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of next-generation monoclonal antibodies for oncology and autoimmune disorders. The company leverages a proprietary glyco-engineering platform designed to enhance antibody-dependent cellular cytotoxicity (ADCC), aiming to produce 'bio-better' versions of established therapeutic antibodies. Its lead candidate, SV-001, is an anti-CD20 monoclonal antibody currently being evaluated in Phase 2 clinical trials for the treatment of B-cell lymphomas. Sunvic Bio's pipeline also includes several pre-clinical candidates targeting clinically validated pathways such as EGFR and HER2. By optimizing the glycosylation patterns of antibodies, the company seeks to improve therapeutic potency and patient outcomes. Sunvic Bio is committed to delivering high-efficacy biologic treatments through its integrated R&D and manufacturing capabilities.